News

Results from the phase 3 NEAR-1 and NEAR-2 clinical trials show consistent efficacy and tolerability of the preservative-free, low-dose eye drop in patients with presbyopia.

Results from the phase 3 ATLANTIS study showed amitriptyline was superior to placebo across multiple symptom-based outcomes for patients with IBS.

The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.

In the PROTECT trial, teplizumab preserved β-cell function in newly diagnosed type 1 diabetes patients, slowing the decline of C-peptide levels, but key secondary endpoints, such as time in range and HbA1c, showed numerical trends without statistical significance.

On October 17, 2023, Ardelyx Inc announced the FDA approval of tenapanor (Xphozah) for reducing serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy.

Though primarily observational, this research’s biggest asset is its experimental design and its exploration of viral stimulus-induced bronchial epithelial cell responses from asthmatic donors being treated with tezepelumab.

A recent nationwide cohort study identified statistically significant associations between IBD and DED, as well as increased risks of corneal surface damage.

An analysis of 14 studies revealed that uveitis had an estimated prevalence of 3.27% in Crohn's disease and 1.60% in ulcerative colitis.

This newly-developed prediction model evaluating CAP risk was noted as having demonstrated accuracy, strong discriminatory qualities, and practicability in clinical settings.

Findings from a systematic review and meta-analysis revealed the pooled incidence rate of cerebrovascular accidents in patients with IBD was greater than in the general population.

Despite access to care and health insurance, Hispanic and non-Hispanic Black individuals with diabetes experience poorer glycemic control compared to non-Hispanic White counterparts, revealing persistent racial disparities in healthcare.

Adolescents from socioeconomically disadvantaged backgrounds were less likely to report receiving a vision test, particularly in clinical settings.

This represented the first in human research focused on assessing the best dosing regimen of mannan-conjugated birch pollen allergoids for those with birch pollen–induced allergic rhinoconjunctivitis.

Though rare, pediatric colon cancer often presents in advanced stages—emphasizing the need for awareness of risk factors and the opportunities borne from timely intervention.

Phase 2b data from the AHFIRM trial is anticipated soon. Reau discusses what the agent may show in treating alcohol-associated hepatitis.

Providers identified an increased administrative workload and inadequate biosimilar device training as pain points during a mandatory switch to a biosimilar.

Racial and ethnic disparities in ocular comorbidities significantly contributed to US deaths from 2000 to 2019, particularly among American Indian or Alaska Native and Hispanic individuals.

This new post-hoc analysis of ruxolitinib cream for those with eczema indicates that continued treatment past 8 weeks may lead to further benefit for those with the skin disease.

The proposed denosumab biosimilar, SB16, demonstrated pharmacokinetic bioequivalence, as well as equivalent efficacy, safety, and immunogenicity,

Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.

Use of mirtazapine, nortriptyline, and trazodone among hospitalized patients was associated with a greater risk of CDI.

Presented at Obesity Week 2023, SURMOUNT-3 provides new insight into the effects of tirzepatide in patients with overweight or obesity.

During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response.

Results of a recent systematic review demonstrated no difference in the immunogenicity rates and safety profiles in patients who switched to a biosimilar and those who continued to receive the reference product.

This segment of Dr. Okoye’s interview featured a set of examples of HS patients’ struggles with access to medication, as well as discussion of potential solutions.

Patients with IgA nephropathy experienced nearly 30% proteinuria reduction after 6 months of treatment with SGLT2 inhibitors.

A highlight of different sessions, presentations, and conversations focused on trends and impact of disparities in women's heart health at HFSA 2023.

This new data was presented at EADV in Berlin, with the findings of 3 studies expanding the range of effectiveness of this treatment to 140-weeks for patients with eczema.